跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
RYALTRIS - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
RYALTRIS
Authorized
STANDARD
RYALTRIS
Glenmark Specialty SA
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
9ed94d2bc2651de6
Company
Glenmark Specialty SA
Type
Standard
Approval Details
Approval Id
9ed94d2bc2651de6
Drug Approval Canada Name
RYALTRIS
Product Name
RYALTRIS
Status
Marketed
Status Date
2023-03-17
Original Market Date
2023-03-17
Din
02531186
Drug Class
Human
Dosage Form
Spray, Metered Dose
Route Of Administration
Nasal
Schedule
Prescription
Ahfs
52:08.08
Atc Original
R01AD59 MOMETASONE, COMBINATIONS
Atc Name
r 01 ad 59
Aig Number
0264081001
Company Name
Glenmark Specialty SA
Company Address
Place Du Port 2, Neuchâtel, --, Switzerland, 2000
Company Detail Path
/organization/glenmark-specialty-sa
Company Information
Pharmaceutical Company Name
Glenmark Specialty SA
Country Name
Switzerland
Province Name
Neuchâtel
City Name
neuchâtel,neuchâtel,country_ch
Address
place du Port 2
Active Ingredients
OLOPATADINE HYDROCHLORIDE
665 MCG / ACT
MOMETASONE FUROATE (MOMETASONE FUROATE MONOHYDRATE)
25 MCG / ACT
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
9ed94d2bc2651de6
Type
Standard
Back to Health Canada Approvals